Expression and function of efflux drug transporters in the intestine

Pharmacology and Therapeutics

Volumn 109, Issue 1-2, 2006, Pages 137-161

  Takano, Mikihisa ^a   Yumoto, Ryoko ^a   Murakami, Teruo ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

ABC transporter; Breast cancer resistance protein; Multidrug resistance associated protein 2; Oral bioavailability; P glycoprotein; Transporter mediated drug interaction

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CARBAMAZEPINE; CARVEDILOL; CISPLATIN; CYCLOSPORIN; DAUNORUBICIN; DIGOXIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ELACRIDAR; ERYTHROMYCIN; ETOPOSIDE; GEFITINIB; GLYCOPROTEIN P; IRINOTECAN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; MYCOTOXIN; NAVELBINE; RHODAMINE; RIFAMPICIN; TALINOLOL; TOPOTECAN; UNINDEXED DRUG; VERAPAMIL; VERLUKAST; ZOSUQUIDAR;

BREAST CARCINOMA; BREAST TUMOR; CHO CELL; CHROMOSOMAL LOCALIZATION; COLON CARCINOMA; DIARRHEA; DRUG BIOAVAILABILITY; DRUG TRANSPORT; EFFUSION; GASTROINTESTINAL TOXICITY; HUMAN; INTESTINE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; WESTERN BLOTTING;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CARRIER PROTEINS; DRUG RESISTANCE, NEOPLASM; HUMANS; INTESTINES; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PHARMACEUTICAL PREPARATIONS;

EID: 28444484982     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2005.06.005     Document Type: Review

References (244)

1. Y. Adachi, H. Suzuki, and Y. Sugiyama Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in situ and in vitro Pharm Res 20 2003 1163 1169
2. Y. Adachi, H. Suzuki, A.H. Schinkel, and Y. Sugiyama Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen Mol Pharmacol 67 2005 923 928
3. S.A. Adibi Regulation of expression of the intestinal oligopeptide transporter (Pept-1) in health and disease Am J Physiol Gastrointest Liver Physiol 285 2003 G779 G788
4. J.D. Allen, A. van Loevezijn, J.M. Lakhai, M. van der Valk, O. van Tellingen, and G. Reid Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C Mol Cancer Ther 1 2002 417 425
5. J.D. Allen, S.C. van Dort, M. Buitelaar, O. van Tellingen, and A.H. Schinkel Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein Cancer Res 63 2003 1339 1344
6. R. Allikmets, L.M. Schriml, A. Hutchinson, V. Romano-Spica, and M. Dean A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance Cancer Res 58 1998 5337 5339
7. S.V. Ambudkar, C. Kimchi-Sarfaty, Z.E. Sauna, and M.M. Gottesman P-glycoprotein: from genomics to mechanism Oncogene 22 2003 7468 7485
8. J. Bart, H. Hollema, H.J. Groen, E.G. de Vries, N.H. Hendrikse, and D.T. Sleijfer The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours Eur J Cancer 40 2004 2064 2070
9. E.V. Batrakova, S. Li, S.V. Vinogradov, V.Y. Alakhov, D.W. Miller, and A.V. Kabanov Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization J Pharmacol Exp Ther 299 2001 483 493
10. Z. Ben-Ari, H. Weiss-Schmilovitz, J. Sulkes, M. Brown, N. Bar-Nathan, and E. Shaharabani Serum cholestasis markers as predictors of early outcome after liver transplantation Clin Transplant 18 2004 130 136
11. L.Z. Benet, T. Izumi, Y. Zhang, J.A. Silverman, and V.J. Wacher Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery J Control Release 62 1999 25 31
12. R.K. Bhardwaj, H. Glaeser, L. Becquemont, U. Klotz, S.K. Gupta, and M.F. Fromm Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4 J Pharmacol Exp Ther 302 2002 645 650
13. K. Bogman, Y. Zysset, L. Degen, G. Hopfgartner, H. Gutmann, and J. Alsenz P-glycoprotein and surfactants: effect on intestinal talinolol absorption Clin Pharmacol Ther 77 2005 24 32
14. M. Boll, D. Markovich, W.M. Weber, H. Korte, H. Daniel, and H. Murer Expression cloning of a cDNA from rabbit small intestine related to proton-coupled transport of peptides, beta-lactam antibiotics and ACE-inhibitors Pflugers Arch 429 1994 146 149
15. S. Bonin, L. Pascolo, L.S. Croce, G. Stanta, and C. Tiribelli Gene expression of ABC proteins in hepatocellular carcinoma, perineoplastic tissue, and liver diseases Mol Med 8 2002 318 325
16. P. Borst, R. Evers, M. Kool, and J. Wijnholds A family of drug transporters: the multidrug resistance-associated proteins J Natl Cancer Inst 92 2000 1295 1302
17. B. Brodin, C.U. Nielsen, B. Steffansen, and S. Frokjaer Transport of peptidomimetic drugs by the intestinal di/tri-peptide transporter, PepT1 Pharmacol Toxicol 90 2002 285 296
18. M. Buchler, J. Konig, M. Brom, J. Kartenbeck, H. Spring, and T. Horie cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats J Biol Chem 271 1996 15091 15098
19. H. Burger, J.A. Foekens, M.P. Look, M.E. Meijer-van Gelder, J.G. Klijn, and E.A. Wiemer RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response Clin Cancer Res 9 2003 827 836
20. L.M.S. Chan, S. Lowes, and B.H. Hirst The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability Eur J Pharm Sci 21 2004 25 51
21. C.J. Chen, J.E. Chin, K. Ueda, D.P. Clark, I. Pastan, and M.M. Gottesman Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells Cell 7 1986 381 389
22. C. Chen, D. Scott, E. Hanson, J. Franco, E. Berryman, and M. Volberg Impact of Mrp2 on the biliary excretion and intestinal absorption of furosemide, probenecid, and methotrexate using Eisai hyperbilirubinemic rats Pharm Res 20 2003 31 37
23. J. Chianale, V. Vollrath, A.M. Wielandt, S. Miranda, R. Gonzalez, and A.M. Fresno Differences between nuclear run-off and mRNA levels for multidrug resistance gene expression in the cephalocaudal axis of the mouse intestine Biochim Biophys Acta 1264 1995 369 376
24. W.L. Chiou, S.M. Chung, T.C. Wu, and C. Ma A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans Int J Clin Pharmacol Ther 39 2001 93 101
25. W.L. Chiou, C. Ma, T.C. Wu, and H.Y. Jeong Unexpected lack of effect of the rifampin-induced P-glycoprotein on the oral bioavailability of its substrate, talinolol, in humans: implication in phenotyping J Pharm Sci 92 2003 4 7
26. X.Y. Chu, Y. Kato, and Y. Sugiyama Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats Cancer Res 57 1997 1934 1938
27. X.Y. Chu, Y. Kato, K. Ueda, H. Suzuki, K. Niinuma, and C.A. Tyson Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters Cancer Res 58 1998 5137 5143
28. S. Cisternino, C. Mercier, F. Bourasset, F. Roux, and J.M. Scherrmann Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier Cancer Res 64 2004 3296 3301
29. D.E. Clark Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena: 1. Prediction of intestinal absorption J Pharm Sci 88 1999 807 814
30. D.E. Clark Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena: 2. Prediction of blood-brain barrier penetration J Pharm Sci 88 1999 815 821
31. D.E. Clark, and P.D. Grootenhuis Predicting passive transport in silico-history, hype, hope Curr Top Med Chem 3 2003 1193 1203
32. S.P. Cole, G. Bhardwaj, J.H. Gerlach, J.E. Mackie, C.E. Grant, and K.C. Almquist Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line Science 258 1992 1650 1654
33. H.C. Cooray, C.G. Blackmore, L. Maskell, and M.A. Barrand Localisation of breast cancer resistance protein in microvessel endothelium of human brain NeuroReport 13 2002 2059 2063
34. H.C. Cooray, T. Janvilisri, H.W. van Veen, S.B. Hladky, and M.A. Barrand Interaction of the breast cancer resistance protein with plant polyphenols Biochem Biophys Res Commun 317 2004 269 275
35. C. Cordon-Cardo, J.P. O'Brien, J. Boccia, D. Casals, J.R. Bertino, and M.R. Melamed Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues J Histochem Cytochem 38 1990 1277 1287
36. M.M. Cornwell, M.M. Gottesman, and I.H. Pastan Increased vinblastine binding to membrane vesicles from multidrug-resistant KB cells J Biol Chem 261 1986 7921 7928
37. W.C. de Bruin, M.J. Wagenmans, and W.H. Peters Expression of glutathione S-transferase alpha, P1-1 and T1-1 in the human gastrointestinal tract Jpn J Cancer Res 91 2000 310 316
38. M. Demeule, J. Jodoin, E. Beaulieu, M. Brossard, and R. Beliveau Dexamethasone modulation of multidrug transporters in normal tissues FEBS Lett 442 1999 208 214
39. M. Demeule, M. Brossard, S. Turcotte, A. Regina, J. Jodoin, and R. Beliveau Diallyl disulfide, a chemopreventive agent in garlic, induces multidrug resistance-associated protein 2 expression Biochem Biophys Res Commun 324 2004 937 945
40. S. Dey, J. Patel, B.S. Anand, B. Jain-Vakkalagadda, P. Kaliki, and D. Pal Molecular evidence and functional expression of P-glycoprotein (MDR1) in human and rabbit cornea and corneal epithelial cell lines Invest Ophthalmol Vis Sci 44 2003 2909 2918
41. J.E. Diestra, G.L. Scheffer, I. Catala, M. Maliepaard, J.H. Schellens, and R.J. Scheper Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material J Pathol 198 2002 213 219
42. C.G. Dietrich, A. Geier, N. Salein, F. Lammert, E. Roeb, and R.P. Oude Elferink Consequences of bile duct obstruction on intestinal expression and function of multidrug resistance-associated protein 2 Gastroenterology 126 2004 1044 1053
43. L.A. Doyle, and D.D. Ross Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) Oncogene 22 2003 7340 7358
44. L.A. Doyle, W. Yang, L.V. Abruzzo, T. Krogmann, Y. Gao, and A.K. Rishi A multidrug resistance transporter from human MCF-7 breast cancer cells Proc Natl Acad Sci U S A 95 1998 15665 15670
45. S. Drescher, H. Glaeser, T. Murdter, M. Hitzl, M. Eichelbaum, and M.F. Fromm P-glycoprotein-mediated intestinal and biliary digoxin transport in humans Clin Pharmacol Ther 73 2003 223 231
46. G.K. Dresser, and D.G. Bailey The effects of fruit juices on drug disposition: a new model for drug interactions Eur J Clin Invest 33 2003 10 16
47. D. Dürr, B. Stieger, G.A. Kullak-Ublick, K.M. Rentsch, H.C. Steinert, and P.J. Meier St. John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4 Clin Pharmacol Ther 68 2000 598 604
48. P. Ertl, B. Rohde, and P. Selzer Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties J Med Chem 43 2000 3714 3717
49. I.F. Faneyte, P.M. Kristel, and M.J. van de Vijver Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer Anticancer Res 24 2004 2931 2939
50. Y.J. Fei, Y. Kanai, S. Nussberger, V. Ganapathy, F.H. Leibach, and M.F. Romero Expression cloning of a mammalian proton-coupled oligopeptide transporter Nature 368 1994 563 566
51. G.H. Feng, Y. Cai, Z. Jia, D.Q. Yang, H. Chen, and H.C. Jin Interventional therapy of malignant obstructive jaundice Hepatobiliary Pancreat Dis Int 2 2003 300 302
52. C.K. Finch, C.R. Chrisman, A.M. Baciewicz, and T.H. Self Rifampin and rifabutin drug interactions: an update Arch Intern Med 162 2002 985 992
53. A.T. Fojo, K. Ueda, D.J. Slamon, D.G. Poplack, M.M. Gottesman, and I. Pastan Expression of a multidrug-resistance gene in human tumors and tissues Proc Natl Acad Sci U S A 84 1987 265 269
54. G. Fricker, J. Drewe, J. Huwyler, H. Gutmann, and C. Beglinger Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation Br J Pharmacol 118 1996 1841 1847
55. D.G. Friend Digitalis after two centuries (William Withering) Arch Surg 111 1976 14 19
56. M.F. Fromm Importance of P-glycoprotein at blood-tissue barriers Trends Pharmacol Sci 25 2004 423 429
57. M.F. Fromm, H.M. Kauffmann, P. Fritz, O. Burk, H.K. Kroemer, and R.W. Warzok The effect of rifampin treatment on intestinal expression of human MRP transporters Am J Pathol 157 2000 1575 1580
58. U. Fuhr Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humans Clin Pharmacokinet 38 2000 493 504
59. S. Funakoshi, T. Murakami, R. Yumoto, Y. Kiribayashi, and M. Takano Role of P-glycoprotein in pharmacokinetics J Pharm Sci 92 2003 1455 1463
60. A. Geick, M. Eichelbaum, and O. Burk Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin J Biol Chem 276 2001 14581 14587
61. T. Giessmann, K. May, C. Modess, D. Wegner, U. Hecker, and M. Zschiesche Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans Clin Pharmacol Ther 76 2004 192 200
62. T. Giessmann, C. Modess, U. Hecker, M. Zschiesche, P. Dazert, and C. Kunert-Keil CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects Clin Pharmacol Ther 75 2004 213 222
63. M. Goto, S. Masuda, T. Kiuchi, Y. Ogura, F. Oike, and M. Okuda CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation Pharmacogenetics 14 2004 471 478
64. Y. Gotoh, H. Suzuki, S. Kinoshita, T. Hirohashi, Y. Kato, and Y. Sugiyama Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats J Pharmacol Exp Ther 292 2000 433 439
65. T. Gramatte, and R. Oertel Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil Clin Pharmacol Ther 66 1999 239 245
66. T. Gramatte, R. Oertel, B. Terhaag, and W. Kirch Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans Clin Pharmacol Ther 59 1996 541 549
67. B. Grams, A. Harms, S. Braun, C.P. Strassburg, M.P. Manns, and P. Obermayer-Straub Distribution and inducibility by 3-methylcholanthrene of family 1 UDP-glucuronosyltransferases in the rat gastrointestinal tract Arch Biochem Biophys 377 2000 255 265
68. P.A. Gregory, R.H. Lewinsky, D.A. Gardner-Stephen, and P.I. Mackenzie Regulation of UDP glucuronosyltransferases in the gastrointestinal tract Toxicol Appl Pharmacol 199 2004 354 363
69. P. Gros, Y.B. Ben Neriah, J.M. Croop, and D.E. Housman Isolation and expression of a complementary DNA that confers multidrug resistance Nature 323 1986 728 731
70. H.K. Han, J.K. Rhie, D.M. Oh, G. Saito, C.P. Hsu, and B.H. Stewart CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs J Pharm Sci 88 1999 347 350
71. V. Haufroid, M. Mourad, V. van Kerckhove, J. Wawrzyniak, M. De Meyer, and D.C. Eddour The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients Pharmacogenetics 14 2004 147 154
72. P.J. Hauptman, and R.A. Kelly Digitalis Circulation 99 1999 1265 1270
73. L.A. Hazlehurst, N.E. Foley, M.C. Gleason-Guzman, M.P. Hacker, A.E. Cress, and L.W. Greenberger Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line Cancer Res 59 1999 1021 1028
74. L. Henderson, Q.Y. Yue, C. Bergquist, B. Gerden, and P. Arlett St. John's wort (Hypericum perforatum): drug interactions and clinical outcomes Br J Clin Pharmacol 54 2002 349 356
75. T. Hirohashi, H. Suzuki, K. Ito, K. Ogawa, K. Kume, and T. Shimizu Hepatic expression of multidrug resistance-associated protein-like proteins maintained in Eisai hyperbilirubinemic rats Mol Pharmacol 53 1998 1068 1075
76. G.T. Ho, F.M. Moodie, and J. Satsangi Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut 52 2003 759 766
77. S. Hoffmeyer, O. Burk, O. von Richter, H.P. Arnold, J. Brockmoller, and A. Johne Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci U S A 97 2000 3473 3478
78. L. Homolya, A. Varadi, and B. Sarkadi Multidrug resistance-associated proteins: export pumps for conjugates with glutathione, glucuronate or sulfate Biofactors 17 2003 103 114
79. Y. Honda, F. Ushigome, N. Koyabu, S. Morimoto, Y. Shoyama, and T. Uchiumi Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux Br J Pharmacol 143 2004 856 864
80. J. Hong, J.D. Lambert, S.H. Lee, P.J. Sinko, and C.S. Yang Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites Biochem Biophys Res Commun 310 2003 222 227
81. M. Horikawa, Y. Kato, and Y. Sugiyama Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats Pharm Res 19 2002 1345 1353
82. M. Hu, and R.T. Borchardt Mechanism of l-alpha-methyldopa transport through a monolayer of polarized human intestinal epithelial cells (Caco-2) Pharm Res 7 1990 1313 1319
83. M. Hu, P. Subramanian, H.I. Mosberg, and G.L. Amidon Use of the peptide carrier system to improve the intestinal absorption of l-alpha-methyldopa: carrier kinetics, intestinal permeabilities, and in vitro hydrolysis of dipeptidyl derivatives of l-alpha-methyldopa Pharm Res 6 1989 66 70
84. Z.H. Huang, T. Murakami, A. Okochi, R. Yumoto, J. Nagai, and M. Takano Expression and function of P-glycoprotein in rats with glycerol-induced acute renal failure Eur J Pharmacol 406 2000 453 460
85. Z.H. Huang, T. Murakami, A. Okochi, R. Yumoto, J. Nagai, and M. Takano Expression and function of P-glycoprotein in rats with carbon tetrachloride-induced acute hepatic failure J Pharm Pharmacol 53 2001 873 881
86. M. Huber, A. Guhlmann, P.L. Jansen, and D. Keppler Hereditary defect of hepatobiliary cysteinyl leukotriene elimination in mutant rats with defective hepatic anion excretion Hepatology 7 1987 224 228
87. F. Innocenti, S.D. Undevia, J. Ramirez, S. Mani, R.L. Schilsky, and N.J. Vogelzang A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital Clin Pharmacol Ther 76 2004 490 502
88. + coupled transport of p.o. cephalosporins via dipeptide carriers in rabbit intestinal brush-border membranes: difference of transport characteristics between cefixime and cephradine J Pharmacol Exp Ther 247 1988 235 241
89. K. Ito, H. Suzuki, T. Hirohashi, K. Kume, T. Shimizu, and Y. Sugiyama Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR Am J Physiol 272 1997 G16 G22
90. K. Ito, H. Suzuki, and Y. Sugiyama Charged amino acids in the transmembrane domains are involved in the determination of the substrate specificity of rat Mrp2 Mol Pharmacol 59 2001 1077 1085
91. W. Jager, O. Winter, B. Halper, A. Salamon, M. Sartori, and L. Gajdzik Modulation of liver canalicular transport processes by the tyrosine-kinase inhibitor genistein: implications of genistein metabolism in the rat Hepatology 26 1997 1467 1476
92. P.L. Jansen, W.H. Peters, and D.K. Meijer Hepatobiliary excretion of organic anions in double-mutant rats with a combination of defective canalicular transport and uridine 5′-diphosphate-glucuronyltransferase deficiency Gastroenterology 93 1987 1094 1103
93. P.L. Jansen, J.W. van Klinken, M. van Gelder, R. Ottenhoff, and R.P. Elferink Preserved organic anion transport in mutant TR-rats with a hepatobiliary secretion defect Am J Physiol 265 1993 G445 G452
94. B. Ji, K. Ito, H. Suzuki, Y. Sugiyama, and T. Horie Multidrug resistance-associated protein2 (MRP2) plays an important role in the biliary excretion of glutathione conjugates of 4-hydroxynonenal Free Radic Biol Med 33 2002 370 378
95. J.W. Jonker, J.W. Smit, R.F. Brinkhuis, M. Maliepaard, J.H. Beijnen, and J.H. Schellens Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan J Natl Cancer Inst 92 2000 1651 1656
96. J.W. Jonker, M. Buitelaar, E. Wagenaar, M.A. Van Der Valk, G.L. Scheffer, and R.J. Scheper The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria Proc Natl Acad Sci U S A 99 2002 15649 15654
97. R.L. Juliano, and V. Ling A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants Biochim Biophys Acta 455 1976 152 162
98. A.V. Kabanov, E.V. Batrakova, and D.W. Miller Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier Adv Drug Deliv Rev 55 2003 151 164
99. B. Kaplan, K. Lown, R. Craig, M. Abecassis, D. Kaufman, and J. Leventhal Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity Transplantation 67 1999 333 335
100. H.R. Kast, B. Goodwin, P.T. Tarr, S.A. Jones, A.M. Anisfeld, and C.M. Stoltz Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor J Biol Chem 277 2002 2908 2915
101. H.M. Kauffmann, D. Keppler, T.W. Gant, and D. Schrenk Induction of hepatic mrp2 (cmrp/cmoat) gene expression in nonhuman primates treated with rifampicin or tamoxifen Arch Toxicol 72 1998 763 768
102. S. Kawabata, M. Oka, K. Shiozawa, K. Tsukamoto, K. Nakatomi, and H. Soda Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells Biochem Biophys Res Commun 280 2001 1216 1223
103. S. Kawabata, M. Oka, H. Soda, K. Shiozawa, K. Nakatomi, and J. Tsurutani Expression and functional analyses of breast cancer resistance protein in lung cancer Clin Cancer Res 9 2003 3052 3057
104. M. Kawahara, A. Sakata, T. Miyashita, I. Tamai, and A. Tsuji Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice J Pharm Sci 88 1999 1281 1287
105. K. Kjeldsen, and H. Bundgaard Myocardial Na,K-ATPase and digoxin therapy in human heart failure Ann N Y Acad Sci 986 2003 702 707
106. D. Kobayashi, I. Ieiri, T. Hirota, H. Takane, S. Maegawa, and J. Kigawa Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta Drug Metab Dispos 32 2005 94 101
107. I. Koch, R. Weil, R. Wolbold, J. Brockmoller, E. Hustert, and O. Burk Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA Drug Metab Dispos 30 2002 1108 1114
108. K. Koike, G. Conseil, E.M. Leslie, R.G. Deeley, and S.P. Col Identification of proline residues in the core cytoplasmic and transmembrane regions of multidrug resistance protein 1 (MRP1/ABCC1) important for transport function, substrate specificity, and nucleotide interactions J Biol Chem 279 2004 12325 12336
109. J. König, D. Rost, Y. Cui, and D. Keppler Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane Hepatology 29 1999 1156 1163
110. T. Konno, T. Ebihara, K. Hisaeda, T. Uchiumi, T. Nakamura, and T. Shirakusa Identification of domains participating in the substrate specificity and subcellular localization of the multidrug resistance proteins MRP1 and MRP2 J Biol Chem 278 2003 22908 22917
111. M. Kool, M. de Haas, G.L. Scheffer, R.J. Scheper, M.J. van Eijk, and J.A. Juijn Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines Cancer Res 57 1997 3537 3547
112. M. Kool, M. van der Linden, M. de Haas, F. Baas, and P. Borst Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells Cancer Res 59 1999 175 182
113. C.M. Kruijtzer, J.H. Beijnen, H. Rosing, W.W. ten Bokkel Huinink, M. Schot, and R.C. Jewell Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918 J Clin Oncol 20 2002 2943 2950
114. G.A. Kullak-Ublick, and M.B. Becker Regulation of drug and bile salt transporters in liver and intestine Drug Metab Rev 35 2003 305 317
115. I.E. Kuppens, J. Beijnen, and J.H. Schellens Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration Clin Colorectal Cancer 4 2004 163 180
116. H. Kusuhara, Y.H. Han, M. Shimoda, E. Kokue, H. Suzuki, and Y. Sugiyama Reduced folate derivatives are endogenous substrates for cMOAT in rats Am J Physiol 275 1998 G789 G796
117. C.P. Landowski, D. Sun, D.R. Foster, S.S. Menon, J.L. Barnett, and L.S. Welage Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters J Pharmacol Exp Ther 306 2003 778 786
118. V. Lecureur, A. Guillouzo, and O. Fardel Differential regulation of mdr genes in response to 2-acetylaminofluorene treatment in cultured rat and human hepatocytes Carcinogenesis 17 1996 1157 1160
119. Y.J. Lee, H. Kusuhara, and Y. Sugiyama Do multidrug resistance-associated protein-1 and -2 play any role in the elimination of estradiol-17 beta-glucuronide and 2,4-dinitrophenyl-S-glutathione across the blood-cerebrospinal fluid barrier? J Pharm Sci 93 2004 99 107
120. Y.J. Lee, H. Kusuhara, J.W. Jonker, A.H. Schinkel, and Y. Sugiyama Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein J Pharmacol Exp Ther 312 2005 44 52
121. P.G. LeFevre Principles of permeation and distribution P.K. Knoefel Absorption, distribution, transformation and excretion of drugs 1972 Charles C. Thomas Publisher IL, USA
122. B. Liedert, V. Materna, D. Schadendorf, J. Thomale, and H. Lage Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin J Invest Dermatol 121 2003 172 176
123. M. Lindell, M.O. Karlsson, H. Lennernas, L. Pahlman, and M.A. Lang Variable expression of CYP and Pgp genes in the human small intestine Eur J Clin Invest 33 2003 493 499
124. V. Ling, and L.H. Thompson Reduced permeability in CHO cells as a mechanism of resistance to colchicine J Cell Physiol 83 1974 103 116
125. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv Drug Deliv Rev 23 1997 3 25
126. T.W. Loo, M.C. Bartlett, and D.M. Clarke The drug-binding pocket of the human multidrug resistance P-glycoprotein is accessible to the aqueous medium Biochemistry 43 2004 12081 12089
127. M. Maliepaard, M.A. van Gastelen, L.A. de Jong, D. Pluim, R.C. van Waardenburg, and M.C. Ruevekamp-Helmers Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line Cancer Res 59 1999 4559 4563
128. M. Maliepaard, G.L. Scheffer, I.F. Faneyte, M.A. van Gastelen, A.C. Pijnenborg, and A.H. Schinkel Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues Cancer Res 61 2001 3458 3464
129. C. Marzolini, E. Paus, T. Buclin, and R.B. Kim Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance Clin Pharmacol Ther 75 2004 13 33
130. S. Masuda, S. Uemoto, T. Hashida, Y. Inomata, K. Tanaka, and K. Inui Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient Clin Pharmacol Ther 68 2000 98 103
131. S. Masuda, M. Goto, T. Kiuchi, S. Uemoto, T. Kodawara, and H. Saito Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation Liver Transplant 9 2003 1108 1113
132. S. Masuda, S. Uemoto, M. Goto, Y. Fujimoto, K. Tanaka, and K. Inui Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients Clin Pharmacol Ther 75 2004 352 361
133. V. Materna, J. Pleger, U. Hoffmann, and H. Lage RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response Gynecol Oncol 94 2004 152 160
134. U. Mayer, E. Wagenaar, J.H. Beijnen, J.W. Smit, D.K. Meijer, and J. van Asperen Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein Br J Pharmacol 119 1996 1038 1044
135. F. Mayer, H. Stoop, G.L. Scheffer, R. Scheper, J.W. Oosterhuis, and L.H. Looijenga Molecular determinants of treatment response in human germ cell tumors Clin Cancer Res 9 2003 767 773
136. W.M. McDonnell, E. Hitomi, and F.K. Askari Identification of bilirubin UDP-GTs in the human alimentary tract in accordance with the gut as a putative metabolic organ Biochem Pharmacol 51 1996 483 488
137. Y. Mitsunaga, H. Takanaga, H. Matsuo, M. Naito, T. Tsuruo, and H. Ohtani Effect of bioflavonoids on vincristine transport across blood-brain barrier Eur J Pharmacol 395 2000 193 201
138. K. Miyake, L. Mickley, T. Litman, Z. Zhan, R. Robey, and B. Cristensen Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes Cancer Res 59 1999 8 13
139. N. Mizuno, T. Niwa, Y. Yotsumoto, and Y. Sugiyama Impact of drug transporter studies on drug discovery and development Pharmacol Rev 55 2003 425 461
140. A. Morikawa, Y. Goto, H. Suzuki, T. Hirohashi, and Y. Sugiyama Biliary excretion of 17β-estradiol 17β-d-glucuronide is predominantly mediated by cMOAT/MRP2 Pharm Res 17 2000 546 552
141. A.D. Mottino, J.M. Pellegrino, E.E. Guibert, M.G. Roma, and E.A. Rodriguez Garay Comparison of hepatic, renal and intestinal bilirubin UDP-glucuronyl transferase activities in rat microsomes Int J Biochem 20 1988 1113 1116
142. A.D. Mottino, T. Hoffman, L. Jennes, and M. Vore Expression and localization of multidrug resistant protein mrp2 in rat small intestine J Pharmacol Exp Ther 293 2000 717 723
143. A.D. Mottino, J. Cao, L.M. Veggi, F. Crocenzi, M.G. Roma, and M. Vore Altered localization and activity of canalicular Mrp2 in estradiol-17beta-d- glucuronide-induced cholestasis Hepatology 35 2002 1409 1419
144. S. Mouly, and M.F. Paine P-glycoprotein increases from proximal to distal regions of human small intestine Pharm Res 20 2003 1595 1599
145. T. Murakami, R. Yumoto, J. Nagai, and M. Takano Factors affecting the expression and function of P-glycoprotein in rats: drug treatments and diseased states Pharmazie 57 2002 102 107
146. H. Naba, C. Kuwayama, C. Kakinuma, S. Ohnishi, and T. Ogihara Eisai hyperbilirubinemic rat (EHBR) as an animal model affording high drug-exposure in toxicity studies on organic anions Drug Metab Pharmacokinet 19 2004 339 351
147. T. Nakahara, T. Sakaeda, T. Nakamura, T. Tamura, C. Nishioka, and N. Aoyama Chemosensitivity assessed by collagen gel droplet embedded culture drug sensitivity test, and MDR1, MRP1, and MRP2 mRNA expression in human colorectal adenocarcinomas Pharm Res 21 2004 406 412
148. T. Nakanishi, L.A. Doyle, B. Hassel, Y. Wei, K.S. Bauer, and S. Wu Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis Mol Pharmacol 64 2003 1452 1462
149. M. Niemi, J.T. Backman, M.F. Fromm, P.J. Neuvonen, and K.T. Kivisto Pharmacokinetic interactions with rifampicin: clinical relevance Clin Pharmacokinet 42 2003 819 850
150. A.T. Nies, G. Jedlitschky, J. Konig, C. Herold-Mende, H.H. Steiner, and H.P. Schmitt Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain Neuroscience 129 2004 349 360
151. + coupled uphill transport of aminocephalosporins via the dipeptide transport system in rabbit intestinal brush-border membranes J Biol Chem 261 1986 14130 14134
152. C. Ozvegy-Laczka, G. Koblos, B. Sarkadi, and A. Varadi Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition Biochim Biophys Acta 1668 2005 53 63
153. I.K. Pajeva, C. Globisch, and M. Wiese Structure-function relationships of multidrug resistance P-glycoprotein J Med Chem 47 2004 2523 2533
154. R. Panchagnula, and S. Agrawal Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin Int J Pharm 271 2004 1 4
155. R.B. Parker, C.R. Yates, J.E. Soberman, and S.C. Laizure Effects of grapefruit juice on intestinal P-glycoprotein: evaluation using digoxin in humans Pharmacotherapy 23 2003 979 987
156. C.C. Paulusma, and R.P. Oude Elferink The canalicular multispecific organic anion transporter and conjugated hyperbilirubinemia in rat and man J Mol Med 75 1997 420 428
157. C.C. Paulusma, M. Kool, P.J. Bosma, G.L. Scheffer, F. ter Borg, and R.J. Scheper A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome Hepatology 25 1997 1539 1542
158. M.D. Perloff, L.L. von Moltke, J.M. Fahey, J.P. Daily, and D.J. Greenblatt Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture AIDS 14 2000 1287 1289
159. M.D. Perloff, E. Stormer, L.L. von Moltke, and D.J. Greenblatt Rapid assessment of P-glycoprotein inhibition and induction in vitro Pharm Res 20 2003 1177 1183
160. H.M. Prime-Chapman, R.A. Fearn, A.E. Cooper, V. Moore, and B.H. Hirst Differential multidrug resistance-associated protein 1 through 6 isoform expression and function in human intestinal epithelial Caco-2 cells J Pharmacol Exp Ther 311 2004 476 484
161. J. Rengelshausen, C. Goggelmann, J. Burhenne, K.D. Riedel, J. Ludwig, and J. Weiss Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction Br J Clin Pharmacol 56 2003 32 38
162. J.R. Riordan, and V. Ling Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability J Biol Chem 254 1979 12701 12705
163. J.R. Riordan, K. Deuchars, N. Kartner, N. Alon, J. Trent, and V. Ling Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines Nature 316 1985 817 819
164. N. Romiti, G. Tramonti, and E. Chieli Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line Toxicol Appl Pharmacol 183 2002 83 91
165. D. Rost, S. Mahner, Y. Sugiyama, and W. Stremmel Expression and localization of the multidrug resistance-associated protein 3 in rat small and large intestine Am J Physiol Gastrointest Liver Physiol 282 2002 G720 G726
166. S. Ryu, T. Kawabe, S. Nada, and A. Yamaguchi Identification of basic residues involved in drug export function of human multidrug resistance-associated protein 2 J Biol Chem 275 2000 39617 39624
167. H. Saito, and K. Inui Dipeptide transporters in apical and basolateral membranes of the human intestinal cell line Caco-2 Am J Physiol 265 1993 G289 G294
168. T. Sakaeda, T. Nakamura, and K. Okumura Pharmacogenetics of drug transporters and its impact on the pharmacotherapy Curr Top Med Chem 4 2004 1385 1398
169. B. Sarkadi, C. Ozvegy-Laczka, K. Nemet, and A. Varadi ABCG2-a transporter for all seasons FEBS Lett 567 2004 116 120
170. H. Sasabe, A. Tsuji, and Y. Sugiyama Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats J Pharmacol Exp Ther 284 1998 1033 1039
171. T.P. Schaub, J. Kartenbeck, J. Konig, O. Vogel, R. Witzgall, and W. Kriz Expression of the conjugate export pump encoded by the mrp2 gene in the apical membrane of kidney proximal tubules J Am Soc Nephrol 8 1997 1213 1221
172. T.P. Schaub, J. Kartenbeck, J. Konig, H. Spring, J. Dorsam, and G. Staehler Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma J Am Soc Nephrol 10 1999 1159 1169
173. A.H. Schinkel, E. Wagenaar, L. van Deemter, C.A. Mol, and P. Borst Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A J Clin Invest 96 1995 1698 1705
174. E.G. Schuetz, W.T. Beck, and J.D. Schuetz Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells Mol Pharmacol 49 1996 311 318
175. U.I. Schwarz, T. Gramatte, J. Krappweis, A. Berndt, R. Oertel, and O. von Richter Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans Clin Pharmacol Ther 65 1999 283 290
176. U.I. Schwarz, T. Gramatte, J. Krappweis, R. Oertel, and W. Kirch P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans Int J Clin Pharmacol Ther 38 2000 161 167
177. K.W. Scotto, J.L. Biedler, and P.W. Melera Amplification and expression of genes associated with multidrug resistance in mammalian cells Science 232 1986 751 755
178. A.B. Shapiro, K. Fox, P. Lam, and V. Ling Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site Eur J Biochem 259 1999 841 850
179. D.W. Shen, A. Fojo, J.E. Chin, I.B. Roninson, N. Richert, and I. Pastan Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification Science 232 1986 643 645
180. Y. Shibayama, R. Ikeda, T. Motoya, and K. Yamada St. John's Wort (Hypericum perforatum) induces overexpression of multidrug resistance protein 2 (MRP2) in rats: a 30-day ingestion study Food Chem Toxicol 42 2004 995 1002
181. J. Shoda, M. Kano, K. Oda, J. Kamiya, Y. Nimura, and H. Suzuki The expression levels of plasma membrane transporters in the cholestatic liver of patients undergoing biliary drainage and their association with the impairment of biliary secretory function Am J Gastroenterol 6 2001 3368 3378
182. J. Shoda, H. Suzuki, H. Suzuki, Y. Sugiyama, M. Hirouchi, and H. Utsunomiya Novel mutations identified in the human multidrug resistance-associated protein 2 (MRP2/ABCC2) gene in a Japanese patient with Dubin-Johnson syndrome Hepatol Res 27 2003 323 326
183. J. Shoda, T. Miura, H. Utsunomiya, K. Oda, M. Yamamoto, and M. Kano Genipin enhances Mrp2 (Abcc2)-mediated bile formation and organic anion transport in rat liver Hepatology 39 2004 167 178
184. Y. Shono, H. Nishihara, Y. Matsuda, S. Furukawa, N. Okada, and T. Fujita Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes J Pharm Sci 93 2004 877 885
185. W. Siegmund, S. Altmannsberger, A. Paneitz, U. Hecker, M. Zschiesche, and G. Franke Effect of levothyroxine administration on intestinal P-glycoprotein expression: consequences for drug disposition Clin Pharmacol Ther 72 2002 256 264
186. W. Siegmund, K. Ludwig, T. Giessmann, P. Dazert, E. Schroeder, and B. Sperker The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol Clin Pharmacol Ther 72 2002 572 583
187. H. Spahn-Langguth, and P. Langguth Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol Eur J Pharm Sci 12 2001 361 367
188. D. Steinbach, J. Lengemann, A. Voigt, J. Hermann, F. Zintl, and A. Sauerbrey Response to chemotherapy and expression of the genes encoding the multidrug resistance-associated proteins MRP2, MRP3, MRP4, MRP5, and SMRP in childhood acute myeloid leukemia Clin Cancer Res 9 2003 1083 1086
189. P. Stenberg, K. Luthman, and P. Artursson Prediction of membrane permeability to peptides from calculated dynamic molecular surface properties Pharm Res 16 1999 205 212
190. R.H. Stephens, C.A. O'Neill, J. Bennett, M. Humphrey, B. Henry, and M. Rowland Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (-/-) mice Br J Pharmacol 135 2002 2038 2046
191. E. Stormer, L.L. von Moltke, M.D. Perloff, and D.J. Greenblatt P-glycoprotein interactions of nefazodone and trazodone in cell culture J Clin Pharmacol 41 2001 708 714
192. M.V. St-Pierre, M.A. Serrano, R.I. Macias, U. Dubs, M. Hoechli, and U. Lauper Expression of members of the multidrug resistance protein family in human term placenta Am J Physiol Regul Integr Comp Physiol 279 2000 R1495 R1503
193. Y. Sugimoto, and T. Tsuruo DNA-mediated transfer and cloning of a human multidrug-resistant gene of adriamycin-resistant myelogenous leukemia K562 Cancer Res 47 1987 2620 2625
194. Y. Sugiyama, Y. Kato, and X. Chu Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein Cancer Chemother Pharmacol 42 1998 S44 S49
195. H. Suzuki, and Y. Sugiyama Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition Adv Drug Deliv Rev 54 2002 1311 1331
196. T.W. Synold, I. Dussault, and B.M. Forman The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux Nat Med 7 2001 584 590
197. J. Taipalensuu, H. Tornblom, G. Lindberg, C. Einarsson, F. Sjoqvist, and H. Melhus Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers J Pharmacol Exp Ther 299 2001 164 170
198. M. Takano, R. Hasegawa, T. Fukuda, R. Yumoto, J. Nagai, and T. Murakami Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells Eur J Pharmacol 358 1998 289 294
199. K. Takara, K. Takagi, M. Tsujimoto, N. Ohnishi, and T. Yokoyama Digoxin up-regulates multidrug resistance transporter (MDR1) mRNA and simultaneously down-regulates steroid xenobiotic receptor mRNA Biochem Biophys Res Commun 30 2003 116 120
200. O. Takenaka, T. Horie, H. Suzuki, and Y. Sugiyama Different biliary excretion systems for glucuronide and sulfate of a model compound; study using Eisai hyperbilirubinemic rats J Pharmacol Exp Ther 274 1995 1362 1369
201. M. Tamai, Y. Ito, H. Mirura, H. Tsukada, K. Yokogawa, and M. Nomura Conjugated bilirubin induces multidrug resistance-associated protein 2 mRNA expression and in vivo cisplatin resistance in rat hepatoma AH66 cells Anticancer Res 23 2003 4781 4787
202. K. Tanaka, M. Hirai, Y. Tanigawara, K. Ueda, M. Takano, and R. Hori Relationship between expression level of P-glycoprotein and daunorubicin transport in LLC-PK1 cells transfected with human MDR1 gene Biochem Pharmacol 53 1997 741 746
203. F. Tang, H. Ouyang, J.Z. Yang, and R.T. Borchardt Bidirectional transport of rhodamine 123 and Hoechst 33342, fluorescence probes of the binding sites on P-glycoprotein, across MDCK-MDR1 cell monolayers J Pharm Sci 93 2004 1185 1194
204. Y. Tayrouz, R. Ding, J. Burhenne, K.D. Riedel, J. Weiss, and T. Hoppe-Tichy Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40 Clin Pharmacol Ther 73 2003 397 405
205. T. Terada, and K. Inui Peptide transporters: structure, function, regulation and application for drug delivery Curr Drug Metab 5 2004 85 94
206. R. Tian, N. Koyabu, H. Takanaga, H. Matsuo, H. Ohtani, and Y. Sawada Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates Pharm Res 19 2002 802 809
207. R.G. Tirona, W. Lee, B.F. Leake, L.B. Lan, C.B. Cline, and V. Lamba The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4 Nat Med 9 2003 220 224
208. S. Toh, M. Wada, T. Uchiumi, A. Inokuchi, Y. Makino, and Y. Horie Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome Am J Hum Genet 64 1999 739 746
209. B. Trausch, R. Oertel, K. Richter, and T. Gramatte Disposition and bioavailability of the β 1-adrenoceptor antagonist talinolol in man Biopharm Drug Dispos 16 1995 403 414
210. A.E. Trezise, P.R. Romano, D.R. Gill, S.C. Hyde, F.V. Sepulveda, and M. Buchwald The multidrug resistance and cystic fibrosis genes have complementary patterns of epithelial expression EMBO J 11 1992 4291 4303
211. N. Tsuchiya, S. Satoh, H. Tada, Z. Li, C. Ohyama, and K. Sato Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients Transplantation 78 2004 182 187
212. A. Tsuji Tissue selective drug delivery utilizing carrier-mediated transport systems J Control Release 62 1999 239 244
213. A. Tsuji Transporter-mediated drug interactions Drug Metab Pharmacokinet 17 2002 253 274
214. T. Uematsu, M. Yamaoka, R. Doto, H. Tanaka, T. Matsuura, and K. Furusawa Expression of ATP-binding cassette transporter in human salivary ducts Arch Oral Biol 48 2003 87 90
215. A.M. van der Bliek, T. Van der Velde-Koerts, V. Ling, and P. Borst Overexpression and amplification of five genes in a multidrug-resistant Chinese hamster ovary cell line Mol Cell Biol 6 1986 1671 1678
216. A.E. van Herwaarden, J.W. Jonker, E. Wagenaar, R.F. Brinkhuis, J.H. Schellens, and J.H. Beijnen The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine Cancer Res 63 2003 6447 6452
217. C. Verstuyft, S. Strabach, H. El-Morabet, R. Kerb, U. Brinkmann, and L. Dubert Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition Clin Pharmacol Ther 73 2003 51 60
218. O. von Richter, O. Burk, M.F. Fromm, K.P. Thon, M. Eichelbaum, and K.T. Kivisto Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens Clin Pharmacol Ther 75 2004 172 183
219. V.J. Wacher, J.A. Silverman, Y. Zhang, and L.Z. Bene Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics J Pharm Sci 87 1998 1322 1330
220. M. Wada, S. Toh, K. Taniguchi, T. Nakamura, T. Uchiumi, and K. Kohno Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome Hum Mol Genet 7 1998 203 207
221. H. Wakasugi, I. Yano, T. Ito, T. Hashida, T. Futami, and R. Nohara Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein Clin Pharmacol Ther 64 1998 123 128
222. R.B. Wang, C.L. Kuo, L.L. Lien, and E.J. Lien Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors J Clin Pharm Ther 28 2003 203 228
223. M.D. Wessel, P.C. Jurs, J.W. Tolan, and S.M. Muskal Prediction of human intestinal absorption of drug compounds from molecular structure J Chem Inf Comput Sci 38 1998 726 735
224. K. Westphal, A. Weinbrenner, T. Giessmann, M. Stuhr, G. Franke, and M. Zschiesche Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein Clin Pharmacol Ther 68 2000 6 12
225. K. Westphal, A. Weinbrenner, M. Zschiesche, G. Franke, M. Knoke, and R. Oertel Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction Clin Pharmacol Ther 68 2000 345 355
226. D. Williams, and J. Feely Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors Clin Pharmacokinet 41 2002 343 370
227. K. Yanase, S. Tsukahara, S. Asada, E. Ishikawa, Y. Imai, and Y. Sugimoto Gefitinib reverses breast cancer resistance protein-mediated drug resistance Mol Cancer Ther 3 2004 1119 1125
228. W.W. Yew Clinically significant interactions with drugs used in the treatment of tuberculosis Drug Safety 25 2002 111 133
229. K. Yoh, G. Ishii, T. Yokose, Y. Minegishi, K. Tsuta, and K. Goto Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer Clin Cancer Res 10 2004 1691 1697
230. T. Yokooji, T. Murakami, K. Ogawa, R. Yumoto, J. Nagai, and M. Takano Modulation of intestinal transport of 2,4-dinitrophenyl-S-glutathione, a multidrug resistance-associated protein 2 substrate, by bilirubin treatment in rats J Pharm Pharmacol 57 2005 579 585
231. T. Yokose, M. Doy, T. Taniguchi, T. Shimada, M. Kakiki, and T. Horie Immunohistochemical study of cytochrome P450 2C and 3A in human non-neoplastic and neoplastic tissues Virchows Arch 434 1999 401 411
232. A.M. Young, C.E. Allen, and K.L. Audus Efflux transporters of the human placenta Adv Drug Deliv Rev 55 2003 125 132
233. R. Yumoto, T. Murakami, Y. Nakamoto, R. Hasegawa, J. Nagai, and M. Takano Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds J Pharmacol Exp Ther 289 1999 149 155
234. R. Yumoto, T. Murakami, M. Sanemasa, R. Nasu, J. Nagai, and M. Takano Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone Drug Metab Dispos 29 2001 145 151
235. R. Yumoto, T. Murakami, and M. Takano Differential effect of acute hepatic failure on in vivo and in vitro P-glycoprotein functions in the intestine Pharm Res 20 2003 765 771
236. Q.Y. Zhang, D. Dunbar, A. Ostrowska, S. Zeisloft, J. Yang, and L.S. Kaminsky Characterization of human small intestinal cytochromes P-450 Drug Metab Dispos 27 1999 804 809
237. D.W. Zhang, H.M. Gu, D. Situ, A. Haimeur, S.P. Cole, and R.G. Deeley Functional importance of polar and charged amino acid residues in transmembrane helix 14 of multidrug resistance protein 1 (MRP1/ABCC1): identification of an aspartate residue critical for conversion from a high to low affinity substrate binding state J Biol Chem 278 2003 46052 46063
238. D.W. Zhang, H.M. Gu, M. Vasa, M. Muredda, S.P. Cole, and R.G. Deeley Characterization of the role of polar amino acid residues within predicted transmembrane helix 17 in determining the substrate specificity of multidrug resistance protein 3 Biochemistry 42 2003 9989 10000
239. D.W. Zhang, K. Nunoya, M. Vasa, H.M. Gu, A. Theis, and S.P. Cole Transmembrane helix 11 of multidrug resistance protein 1 (MRP1/ABCC1): identification of polar amino acids important for substrate specificity and binding of ATP at nucleotide binding domain 1 Biochemistry 43 2004 413 425
240. S. Zhang, X. Yang, and M.E. Morris Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport Mol Pharmacol 65 2004 1208 1216
241. H. Zheng, S. Webber, A. Zeevi, E. Schuetz, J. Zhang, and P. Bowman Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms Am J Transplant 3 2003 477 483
242. H. Zheng, A. Zeevi, E. Schuetz, J. Lamba, K. McCurry, and B.P. Griffith Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism J Clin Pharmacol 44 2004 135 140
243. S. Zhou, L.Y. Lim, and B. Chowbay Herbal modulation of P-glycoprotein Drug Metab Rev 36 2004 57 104
244. C. Zimmermann, H. Gutmann, P. Hruz, J.P. Gutzwiller, C. Beglinger, and J. Drewe Mapping of MDR1 and MRP1-5 mRNA expression along the human intestinal tract Drug Metab Dispos 33 2005 219 224